Specific NOX4 Inhibition Preserves Mitochondrial Function and Dampens Kidney Dysfunction Following

Tomas A Schiffer1, Lucas Rannier Ribeiro Antonino Carvalho1, Drielle Guimaraes1

  • 1Department of Physiology and Pharmacology, Karolinska Institutet, 17165 Solna, Sweden.

PubMed

Insights

A novel NOX4 inhibitor (GLX7013114) significantly improved kidney function and preserved mitochondrial health in a mouse model of ischemia-reperfusion induced acute kidney injury (AKI). This suggests a potential therapeutic strategy for preventing AKI in high-risk patients.

Area of Science:

  • Nephrology
  • Cardiovascular Research
  • Mitochondrial Biology

Background:

  • Acute kidney injury (AKI) is a critical condition with high mortality, often caused by ischemia-reperfusion (IR) injury.
  • NADPH oxidases (NOXs), particularly NOX4, are implicated in oxidative stress during IR injury.
  • Therapeutic strategies targeting NOX4 for IR-induced AKI are underexplored.

Purpose of the Study:

  • To evaluate the therapeutic potential of a specific NOX4 inhibitor, GLX7013114, in a mouse model of IR-induced AKI.
  • To assess the effects of NOX4 inhibition on kidney function and mitochondrial health post-IR injury.

Main Methods:

  • Male C57BL/6J mice underwent kidney IR injury (20 min clamp).
  • GLX7013114 was administered during reperfusion via osmotic minipump.
  • Kidney function (GFR), mitochondrial respiration, histopathology, and apoptosis were assessed after 3 days.

Main Results:

  • NOX4 inhibition significantly improved glomerular filtration rate (GFR) and reduced blood urea nitrogen levels.
  • GLX7013114 attenuated tubular injury and renal apoptosis.
  • Mitochondrial function was preserved, with enhanced Nrf2 Ser40 phosphorylation observed.

Conclusions:

  • Specific NOX4 inhibition during reperfusion effectively preserves kidney and mitochondrial function in IR-induced AKI.
  • GLX7013114 demonstrates significant therapeutic potential for preventing AKI.
  • These findings may inform future clinical treatments for high-risk hospitalized patients susceptible to AKI.